SL Science Holding is a Taipei-headquartered Cayman issuer that reached Nasdaq by wrapping a cosmetics-scale Taiwan operator inside a special-purpose acquisition company and then asking public investors to underwrite a fully preclinical cell-therapy story. The combination closed in mid-June and ordinary shares began trading under SLBT a few sessions later. What changed is not the science calendar so much as the capital-markets wrapper: a deal that assigned the operating subsidiary an implied equity value in the billions against a private placement that added only a thin cash layer. The investment debate is whether a licensed gamma-delta and Armed-T platform, still without an investigational new drug filing, can support a public capitalization that sits far above the cash and far above the only revenue the group actually books.
The operating company still earns its keep from milk-derived and plant-extract cosmetics sold into Taiwan wholesale channels, not from oncology. Full-year sales contracted as management shifted away from retail toward distributors so that staff could chase preclinical work. Year-end cash sat near $1 million before the placement. Pro forma liquidity after that placement is about $9 million. That is the entire disclosed public-company runway against remaining license milestones that, if the programs actually advance, run into the tens of millions at the licensors. The market is therefore paying for a regulatory-option story whose cash account is still sized for a private lab, not for two IND campaigns.
The agency has already told the blood-cancer program that nonclinical, manufacturing, and release-testing packages were not ready for an investigational filing. An orphan-drug request for glioblastoma was declined and held in abeyance pending more animal work. The next year resolves a simple question: does SL Science convert Drug Master Files and conference posters into accepted filings before cash and related-party milestone math force another raise, or does the equity remain a listed option on paperwork that has not yet opened a clinic?